Intensification of Antiretroviral Therapy with a CCR5 Antagonist in Patients with Chronic HIV-1 Infection: Effect on T Cells Latently Infected

Sigmoid Th17 populations, the HIV latent reservoir, and microbial translocation in men on long-term antiretroviral therapy

(2011) Duncan Chege et al.   AIDS

Relationship Between Residual Plasma Viremia and the Size of HIV Proviral DNA Reservoirs in Infected Individuals Receiving Effective Antiretroviral Therapy

(2011) Tae-Wook Chun et al.   JOURNAL OF INFECTIOUS DISEASES

Clonal Sequences Recovered from Plasma from Patients with Residual HIV-1 Viremia and on Intensified Antiretroviral Therapy Are Identical to Replicating Viral RNAs Recovered from Circulating Resting CD4+ T Cells

(2011) J. A. Anderson et al.   JOURNAL OF VIROLOGY

Effect of raltegravir-containing intensification on HIV burden and T-cell activation in multiple gut sites of HIV-positive adults on suppressive antiretroviral therapy

(2010) Steven A Yukl et al.   AIDS

Rebound of plasma viremia following cessation of antiretroviral therapy despite profoundly low levels of HIV reservoir: implications for eradication

(2010) Tae-Wook Chun et al.   AIDS

Short‐Course Raltegravir Intensification Does Not Reduce Persistent Low‐Level Viremia in Patients with HIV‐1 Suppression during Receipt of Combination Antiretroviral Therapy

(2010) D. McMahon et al.   CLINICAL INFECTIOUS DISEASES

Treatment Intensification Has no Effect on the HIV-1 Central Nervous System Infection in Patients on Suppressive Antiretroviral Therapy

(2010) Aylin Yilmaz et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Maraviroc versus Efavirenz, Both in Combination with Zidovudine‐Lamivudine, for the Treatment of Antiretroviral‐Naive Subjects with CCR5‐Tropic HIV‐1 Infection

(2010) David A. Cooper et al.   JOURNAL OF INFECTIOUS DISEASES

Differences in HIV Burden and Immune Activation within the Gut of HIV‐Positive Patients Receiving Suppressive Antiretroviral Therapy

(2010) Steven A. Yukl et al.   JOURNAL OF INFECTIOUS DISEASES

HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects

(2010) Maria J Buzón et al.   NATURE MEDICINE

Effects of Maraviroc and Efavirenz on Markers of Immune Activation and Inflammation and Associations with CD4+ Cell Rises in HIV-Infected Patients

(2010) Nicholas Funderburg et al.   PLoS One

Microbial translocation is associated with residual viral replication in HAART-treated HIV+ subjects with

(2009) Silvia Baroncelli et al.   JOURNAL OF CLINICAL VIROLOGY

No Evidence for Decay of the Latent Reservoir in HIV‐1–Infected Patients Receiving Intensive Enfuvirtide‐Containing Antiretroviral Therapy

(2009) Rajesh T. Gandhi et al.   JOURNAL OF INFECTIOUS DISEASES

HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation

(2009) Nicolas Chomont et al.   NATURE MEDICINE

The integrin  4 7 forms a complex with cell-surface CD4 and defines a T-cell subset that is highly susceptible to infection by HIV-1

(2009) C. Cicala et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Treatment intensification does not reduce residual HIV-1 viremia in patients on highly active antiretroviral therapy

(2009) J. B. Dinoso et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The Spanish HIV BioBank: a model of cooperative HIV research

(2009) Isabel Garcia-Merino et al.   Retrovirology

Chemokine Coreceptor Signaling in HIV-1 Infection and Pathogenesis

(2009) Yuntao Wu et al.   PLoS Pathogens

Persistence of HIV in Gut‐Associated Lymphoid Tissue despite Long‐Term Antiretroviral Therapy

(2008) Tae‐Wook Chun et al.   JOURNAL OF INFECTIOUS DISEASES

Immune reconstitution in the sigmoid colon after long-term HIV therapy

(2008) P M Sheth et al.   Mucosal Immunology

Maraviroc for Previously Treated Patients with R5 HIV-1 Infection

(2008) Roy M. Gulick et al.   NEW ENGLAND JOURNAL OF MEDICINE

Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy

(2008) S. Palmer et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

HIV rebounds from latently infected cells, rather than from continuing low-level replication

(2008) B. Joos et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA